Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-076-7 | CAS number: 51-03-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Published data
Data source
Reference
- Title:
- Human in vivo percutaneous absorption of Pyrethrin and Piperonyl Butoxide
- Author:
- Wester, R.C., Bucks, D.A.W., Maibach, H.I.
- Year:
- 1 994
- Bibliographic source:
- Food Chem Toxicol. 32, 51-53
Materials and methods
- Principles of method if other than guideline:
- The dermal absorption of the active substance applied with a formulation containing 3% Piperonyl butoxide was studied by Wester et al.(1994)
14C-labelled Piperonyl butoxide (3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm²) was applied to the ventral forearms of six human volunteers .
Percutaneous absorption was determined by 14C urinary excretion.
The forearms were thoroughly cleaned with soap and water 30 minutes after application. Percutaneous absorption was determined by urinary cumulative excretion of the 14C-radiolabel following application of the above dose. - GLP compliance:
- not specified
Test material
- Reference substance name:
- Piperonyl butoxide
- IUPAC Name:
- Piperonyl butoxide
- Details on test material:
- 14C-labelled Piperonyl butoxide (3.4 mCi/mmol
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- human
- Sex:
- male
Administration / exposure
- Type of coverage:
- not specified
- Vehicle:
- other:
- Doses:
- 3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm²
- No. of animals per group:
- 6 male volunteers
- Control animals:
- no
- Details on study design:
- 100 µl of a formualtion containing pyridine and piperonyl butoxide were applied to the foreamr (44cm²)
Results and discussion
- Signs and symptoms of toxicity:
- not specified
- Dermal irritation:
- not specified
- Absorption in different matrices:
- no data
- Total recovery:
- no data
Percutaneous absorption
- Dose:
- 75.8 µg/ cm²
- Parameter:
- percentage
- Absorption:
- 2.1 %
- Remarks on result:
- other: 24 h
- Conversion factor human vs. animal skin:
- no applicable
Any other information on results incl. tables
Dermal absorption of Piperonyl butoxide was determined to be 2.1±0.6% of the dose applied to ventral forearm skin of six male volunteers. The calculated half-life for14C excretion of Piperonyl butoxide was 32 h.
Applicant's summary and conclusion
- Conclusions:
- Dermal absorption was 2.1% in a human volunteer study.
- Executive summary:
The dermal absorption of the active substance applied with a formulation containing 3% Piperonyl butoxide was studied by Wester et al.(1994) who applied 14C-labelled Piperonyl butoxide (3.4 mCi/mmol - equivalent to a dose of 75.8 µg Piperonyl butoxide/ cm2) to the ventral forearms of six human volunteers .
The forearms were thoroughly cleaned with soap and water 30 minutes after application. Percutaneous absorption was determined by urinary cumulative excretion of the 14C-radiolabel following application of the above dose.
In this study the dermal absorption of Piperonyl butoxide was determined to be 2.1±0.6% of the dose applied to ventral forearm skin. The calculated half-life for 14C excretion of Piperonyl butoxide was 32 h.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.